Elios Vision Acquired by Bausch + Lomb After Strategic Guidance from Outcome Capital
Deal News | Jan 09, 2025 | Outcome Capital LLC
Outcome Capital LLC, a specialized advisory and investment banking firm, successfully guided Elios Vision in its growth and acquisition by Bausch + Lomb Corporation. Elios Vision developed a pioneering minimally invasive glaucoma surgery (MIGS) technique using an excimer laser, aimed at reducing intraocular pressure with fewer risks compared to traditional methods. The firm's collaboration started in 2019, recognizing the immense potential of Elios Vision's technology in the $2.5 billion glaucoma treatment market. Elios Vision's technology is marketed in the EU and is awaiting FDA approval in the U.S. this year. Outcome Capital's strategic guidance positioned Elios Vision as a leader in next-gen glaucoma treatments, securing necessary funding and preparing the company for acquisition, significantly enhancing Bausch + Lomb's glaucoma portfolio.
Sectors
- Life Sciences
- Healthcare Advisory & Investment Banking
- Medical Technology
Geography
- United States – Elios Vision is seeking FDA approval in the U.S., and Outcome Capital is based in Boston, marking key geography in the article.
- European Union – Elios Vision's technology is marketed and sold in the EU, highlighting its geographical market presence.
Industry
- Life Sciences – The article focuses on Elios Vision, a company developing technology in the life sciences domain, specifically for glaucoma treatment.
- Healthcare Advisory & Investment Banking – Outcome Capital provides strategic advisory services within the healthcare industry, helping companies secure financing and facilitate acquisitions.
- Medical Technology – Elios Vision is involved in the development of innovative medical technologies for glaucoma treatment, a significant healthcare market segment.
Financials
- $2.5 billion – Market size of the glaucoma treatment segment in which Elios Vision operates.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Elios Vision, Inc. | Target Company | Company | Developer of the ELIOS procedure for glaucoma treatment, recently acquired by Bausch + Lomb. |
| Outcome Capital LLC | Corporate Finance Advisor | Company | A specialized advisory and investment banking firm guiding Elios Vision in strategic growth and acquisition. |
| Bausch + Lomb Corporation | Acquirer | Company | A prominent global eye health company acquiring Elios Vision to enhance its glaucoma treatment portfolio. |
| Dr. Oded Ben-Joseph | Managing Partner at Outcome Capital | Person | Instrumental in advising and positioning Elios Vision for acquisition. |
| Arnold Freedman | Managing Partner at Outcome Capital | Person | Commented on the strategic positioning of Elios Vision as an acquisition target. |